Sanofi’s recent stock rout underscores the pressure on the French drug maker to redouble its efforts in the hunt for new medicines.
“My belief is that [the stock price] recovery will come because of an incredible disconnect between the fundamentals of the company and its valuation,” finance chief Jean-Baptiste de Chatillon told Reuters last week.. For Markus Manns, portfolio manager at Germany-based Union Investment, which holds Sanofi stock, this is misplaced optimism following the failure of amcenestrant.
That is piling pressure on Hudson, a former Novartis executive, who was tasked with reviving the share price and simplifying the business centred on vaccines, immunology, rare diseases and oncology.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: